• Wondering whether Globus Medical's current share price lines up with its underlying value, or if the market is missing something important.
• The stock recently closed at US$84.77, with returns of 19.3% over 1 year and 63.6% over 3 years, while the last 7 and 30 days show modest declines of 2.7% and 4.0% and a 2.9% decline year to date.
• Recent coverage around Globus Medical has focused on its role in the medical devices space and how investors are weighing growth expectations against execution risks. This context helps explain why the share price can move in short bursts, even when the longer term return profile, like the 40.2% over 5 years, looks different.
• Globus Medical currently scores a 4 out of 6 on our valuation checks, suggesting several areas where the share price and underlying metrics may not fully align. Next we will look at the usual valuation tools like P/E, cash flows and peer comparisons, then finish with a more complete way to think about what this score really means for long term investors.

Approach 1: Globus Medical Discounted Cash Flow (DCF) Analysis

A DCF model takes Globus Medical's expected future cash flows, then discounts them back to today to estimate what the business might be worth right now in dollar terms. It is essentially asking what a stream of future cash flows is worth in today's money.

For Globus Medical, the model starts with last twelve months free cash flow of about $603.6 million. Analysts provide estimates out to 2027, including projected free cash flow of $510.85 million in 2027, and Simply Wall St then extrapolates cash flows further using its own growth assumptions.

The ten year projections range from $395.6 million in 2026 to $663.9 million in 2035, with each year discounted back to today. Adding these discounted values and a terminal value gives an estimated intrinsic value of $83.88 per share using a 2 Stage Free Cash Flow to Equity model.

Set against the recent share price of $84.77, the DCF suggests Globus Medical is about 1.1% overvalued, which is effectively in line with the current market pricing.

Result: ABOUT RIGHT

Globus Medical is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Globus Medical Price vs Earnings

For a profitable company like Globus Medical, the P/E ratio is a useful way to relate what you pay per share to the earnings that each share generates. Investors usually accept a higher P/E when they expect stronger earnings growth or see lower risk, and look for a lower P/E when growth is more modest or risks feel higher.

Globus Medical currently trades on a P/E of 21.32x. That sits below the Medical Equipment industry average P/E of 26.81x, and also below the peer group average of 48.39x. Simply Wall St's Fair Ratio for Globus Medical is 22.68x. This is the P/E level it estimates would be reasonable given the company’s earnings growth profile, margins, industry, market cap and risk characteristics.

The Fair Ratio aims to be more tailored than a simple peer or industry comparison because it adjusts for factors like growth, profitability, size and specific risks rather than assuming all companies deserve the same multiple. Compared with this Fair Ratio of 22.68x, the current P/E of 21.32x suggests the shares are somewhat undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Globus Medical Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St's Community page you can use Narratives, where you write a short story about Globus Medical that links your view of its products, competition and risks to explicit forecasts for revenue, earnings and margins. These forecasts then flow through to an assumed fair value you can compare with the current price. The valuation updates automatically when new earnings or news arrive. You can also see how different investors frame the same stock, such as a more optimistic view that lines up with the US$106 high analyst target or a more cautious view closer to the US$65 low target.

Do you think there's more to the story for Globus Medical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.